White Pine Capital LLC bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 3,056 shares of the biopharmaceutical company’s stock, valued at approximately $455,000.
A number of other institutional investors have also added to or reduced their stakes in GILD. BlackRock Inc. purchased a new position in shares of Gilead Sciences during the second quarter worth about $15,393,785,000. State Street Corp increased its position in shares of Gilead Sciences by 2.3% in the second quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock worth $7,734,099,000 after purchasing an additional 1,357,967 shares during the last quarter. Amundi raised its stake in Gilead Sciences by 10.7% in the first quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock valued at $1,468,836,000 after purchasing an additional 1,018,976 shares in the last quarter. Legal & General Group Plc purchased a new stake in Gilead Sciences in the second quarter valued at approximately $1,316,606,000. Finally, Deutsche Bank AG purchased a new stake in Gilead Sciences in the second quarter valued at approximately $918,387,000. 83.67% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Several equities research analysts have issued reports on GILD shares. Weiss Ratings upgraded shares of Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, September 14th. Barclays boosted their price target on shares of Gilead Sciences from $145.00 to $160.00 and gave the stock an “equal weight” rating in a research note on Monday. JPMorgan Chase & Co. increased their price target on shares of Gilead Sciences from $170.00 to $190.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Bank of America raised their price objective on shares of Gilead Sciences from $168.00 to $172.00 and gave the company a “buy” rating in a research report on Tuesday, October 20th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $184.00 price objective on shares of Gilead Sciences in a report on Friday, October 30th. Twenty-three analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $171.63.
Check Out Our Latest Research Report on GILD
More Gilead Sciences News
Here’s some of the latest news about GILD:
- Positive Sentiment: Gilead signed royalty-free voluntary licensing agreements with three generic manufacturers to support potential future access to investigational obeldesivir for Ebola Bundibugyo virus disease post-exposure prevention in 127 primarily low- and lower-middle-income countries. This may broaden access and strengthen Gilead’s profile, though the drug is not yet approved. Reuters article
- Neutral Sentiment: Barclays raised its price target from $145 to $160 but kept an “equal weight” rating. The higher target is an improvement, although it remains below the stock’s cited recent price, signaling a measured view of further upside. Barclays ratings
- Negative Sentiment: Zacks Research made mixed earnings revisions: it lowered its Q4 2026 EPS estimate to $1.31 from $2.14 and its FY2026 estimate to a loss of $0.86 per share from a loss of $0.65, while slightly raising its Q1 2028 forecast. The near-term cuts may weigh on sentiment. Zacks Research forecast article
Insider Buying and Selling at Gilead Sciences
In other Gilead Sciences news, Director Anthony Welters sold 18,000 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the transaction, the director directly owned 12,894 shares of the company’s stock, valued at approximately $1,916,306.28. This trade represents a 58.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 102,619 shares of the business’s stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $175.16, for a total transaction of $17,974,744.04. Following the completion of the sale, the chief executive officer owned 551,683 shares of the company’s stock, valued at approximately $96,632,794.28. The trade was a 15.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 211,709 shares of company stock valued at $35,234,427. 0.30% of the stock is currently owned by corporate insiders.
Gilead Sciences Price Performance
GILD opened at $167.58 on Tuesday. The stock has a 50-day moving average price of $155.43 and a 200-day moving average price of $141.94. Gilead Sciences, Inc. has a 12-month low of $116.88 and a 12-month high of $176.58. The company has a current ratio of 1.38, a quick ratio of 1.22 and a debt-to-equity ratio of 1.84. The stock has a market capitalization of $207.86 billion, a P/E ratio of -53.03 and a beta of 0.35.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, beating analysts’ consensus estimates of $2.19 by $0.36. The company had revenue of $8.30 billion for the quarter, compared to analysts’ expectations of $7.81 billion. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. Gilead Sciences’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same period last year, the firm posted $2.47 EPS. Equities analysts predict that Gilead Sciences, Inc. will post -0.97 earnings per share for the current fiscal year.
Gilead Sciences Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Shareholders of record on Tuesday, December 15th will be paid a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 annualized dividend and a yield of 2.0%. Gilead Sciences’s dividend payout ratio is currently -103.80%.
Gilead Sciences Company Profile
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.
Read More
- Five stocks we like better than Gilead Sciences
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
